MARKET

ERAS

ERAS

Erasca, Inc.
NASDAQ
1.420
+0.040
+2.90%
After Hours: 1.450 +0.03 +2.11% 17:13 04/23 EDT
OPEN
1.370
PREV CLOSE
1.380
HIGH
1.550
LOW
1.370
VOLUME
2.16M
TURNOVER
--
52 WEEK HIGH
3.450
52 WEEK LOW
1.010
MARKET CAP
402.24M
P/E (TTM)
-2.0538
1D
5D
1M
3M
1Y
5Y
1D
Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday
Benzinga · 2d ago
Weekly Report: what happened at ERAS last week (0414-0418)?
Weekly Report · 2d ago
Weekly Report: what happened at ERAS last week (0407-0411)?
Weekly Report · 04/14 09:22
Weekly Report: what happened at ERAS last week (0331-0404)?
Weekly Report · 04/07 09:22
Erasca Insiders Lose Out As Stock Sinks To US$1.21
Simply Wall St · 04/02 11:19
Morgan Stanley Keeps Their Buy Rating on Erasca (ERAS)
TipRanks · 03/31 12:06
Weekly Report: what happened at ERAS last week (0324-0328)?
Weekly Report · 03/31 09:25
Erasca (ERAS) Gets a Buy from J.P. Morgan
TipRanks · 03/30 13:55
More
About ERAS
More
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.
Recently
Symbol
Price
%Change

Webull offers Erasca Inc stock information, including NASDAQ: ERAS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ERAS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ERAS stock methods without spending real money on the virtual paper trading platform.